Tenaya CEO Faraz Ali to headline key gene therapy conferences this fall

Tenaya CEO Faraz Ali to headline key gene therapy conferences this fall

Christina Sanchez
Christina Sanchez
2 Min.
Diagram of a human heart highlighting the valves with numbered and text annotations, labeled as a patent for a heart valve.

Tenaya CEO Faraz Ali to headline key gene therapy conferences this fall

Faraz Ali, CEO of Tenaya Therapeutics, will take part in two major industry events this autumn. His appearances include panel discussions and a company presentation. Both conferences focus on advancements in gene and cell therapy.

On October 6, 2025, Ali will attend the Cell & Gene Meeting on the Mesa. There, he joins a panel titled Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development. He will also deliver a company presentation at the same event.

Later, on October 21, 2025, Ali will participate in the Chardan Annual Genetic Medicines Conference. His role includes a panel discussion called *In Vivo Gene Therapies for Genetic Cardiac Diseases*. A live webcast of this session will be available on Tenaya's website. Tenaya Therapeutics currently has one preclinical programme, TN-301, targeting three conditions: DMD cardiomyopathy, HFpEF, and genetic dilated cardiomyopathy. No other preclinical projects for cardiovascular or genetic disorders are listed in the company's latest updates.

Ali's participation in these conferences highlights Tenaya's engagement in gene and cell therapy research. The events provide a platform to discuss the company's work, including its sole preclinical programme, TN-301. Both sessions will be accessible to viewers online or in person.

Neueste Nachrichten